Inclusion Criteria:  Male or female; Age 3-18 years old; Diagnosis of Alport syndrome by genetic testing (documented mutation in a gene associated with Alport syndrome, including COL4A3, COL4A4, or COL4A5) or histologic assessment using electron microscopy; Screening eGFR ≥ 90 mL/min/1.73 m2; ACE inhibitor and/or ARB, the dosing regimen should be stable for at least 4 weeks prior to screening; No antirheumatic drugs such as hydroxychloroquine have been used; Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures;  Exclusion Criteria:  Causes of chronic kidney disease aside from Alport syndrome (including but not limited to other heritable disorders leading to chronic kidney disease, diabetic nephropathy, hypertensive nephropathy, lupus nephritis, IgA nephropathy); Prior exposure to hydroxychloroquine; Ongoing chronic hemodialysis or peritoneal dialysis therapy; Renal transplant recipient; Any clinically significant illness within 4 weeks before screening or surgical or medical condition (other than Alport syndrome) that could interfere with the subject's study compliance; confound the study results; impact subject safety; or significantly alter the absorption, distribution, metabolism, or excretion of drugs; Participation in other interventional clinical studies; Known hypersensitivity to any component of the study drug.